Monte Rosa Therapeutics (GLUE) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Registrant Name	Monte Rosa Therapeutics, Inc.
Entity Central Index Key	0001826457
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		46,713,908
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Security12b Title	Common stock, par value $0.0001 per share
Trading Symbol	GLUE
Security Exchange Name	NASDAQ
Entity File Number	001-40522
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	84-3766197
Entity Address Address Line1	645 Summer Street
Entity Address, Address Line Two	Suite 102
Entity Address City Or Town	Boston
Entity Address State Or Province	MA
Entity Address Postal Zip Code	02210
City Area Code	617
Local Phone Number	949-2643
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 103,664	$ 346,071
Marketable securities	190,481	0
Prepaid expenses and other current assets	2,900	2,595
Total current assets	297,045	348,666
Property and equipment, net	15,205	12,325
Operating lease right-of-use assets	47,102	0
Restricted cash	5,320	5,338
Other long-term assets	384	0
Total assets	365,056	366,329
Current liabilities:
Accounts payable	4,294	6,558
Accrued expenses and other current liabilities	7,817	10,080
Current portion of operating lease liability	2,662	0
Total current liabilities	14,773	16,638
Defined benefit plan liability	2,138	2,176
Operating lease liability	46,095	0
Total liabilities	63,006	18,814
Commitments and contingencies
Stockholders' equity
Common stock, $0.0001 par value; 500,000,000 shares authorized, 46,873,974 shares issued and 46,684,658 shares outstanding as of June 30, 2022; and 500,000,000 shares authorized, 46,794,295 shares issued and 46,535,966 shares outstanding as of December 31, 2021	5	5
Additional paid-in capital	476,939	471,566
Accumulated other comprehensive loss	(2,458)	(2,021)
Accumulated deficit	(172,436)	(122,035)
Total stockholders' equity	302,050	347,515
Total liabilities and stockholders' equity	$ 365,056	$ 366,329

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par or stated value per share	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares, issued	46,873,974	46,794,295
Common stock shares outstanding	46,684,658	46,535,966

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 20,936	$ 14,637	$ 38,851	$ 23,910
General and administrative	6,295	3,486	12,682	5,717
Total operating expenses	27,231	18,123	51,533	29,627
Loss from operations	(27,231)	(18,123)	(51,533)	(29,627)
Other income (expense):
Interest income, net	628	14	777	20
Foreign currency exchange gain (loss), net	134	(296)	230	(114)
Gain on disposal of fixed assets			125
Changes in fair value of preferred stock tranche obligations, net	0	0	0	(960)
Total other income (expense)	762	(282)	1,132	(1,054)
Net loss	$ (26,469)	$ (18,405)	$ (50,401)	$ (30,681)
Net loss per share attributable to common stockholders-basic	$ (0.57)	$ (3.63)	$ (1.08)	$ (9.03)
Net loss per share attributable to common stockholders-diluted	$ (0.57)	$ (3.63)	$ (1.08)	$ (9.03)
Weighted-average number of common shares used in computing net loss per share-basic	46,668,369	5,070,554	46,632,279	3,399,174
Weighted-average number of common shares used in computing net loss per share-diluted	46,668,369	5,070,554	46,632,279	3,399,174
Comprehensive loss:
Net loss	$ (26,469)	$ (18,405)	$ (50,401)	$ (30,681)
Provision for pension benefit obligation	33	(495)	67	(359)
Unrealized loss on available-for-sale securities	(358)		(504)
Comprehensive loss	$ (26,794)	$ (18,900)	$ (50,838)	$ (31,040)

Condensed Combined and Consolid

Condensed Combined and Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Series B Convertible Preferred Stock	Series C Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at Dec. 31, 2020	$ (48,728)				$ 1	$ 404	$ (1,056)	$ (48,077)
Balance (in shares) at Dec. 31, 2020					1,685,534
Balance at Dec. 31, 2020		$ 67,764
Balance (in shares) at Dec. 31, 2020		53,631,514
Restricted common stock vesting, Shares					36,565
Issuance of convertible preferred stock, net of issuance costs			$ 68,571	$ 94,837
Issuance of convertible preferred stock, net of issuance costs, shares			24,000,000	32,054,521
Provision for pension benefit obligation	136						136
Stock-based compensation expense	252					252
Net loss	(12,276)							(12,276)
Balance at Mar. 31, 2021	(60,616)				$ 1	656	(920)	(60,353)
Balance (in shares) at Mar. 31, 2021					1,722,099
Balance at Mar. 31, 2021		$ 231,172
Balance (in shares) at Mar. 31, 2021		109,686,035
Balance at Dec. 31, 2020	(48,728)				$ 1	404	(1,056)	(48,077)
Balance (in shares) at Dec. 31, 2020					1,685,534
Balance at Dec. 31, 2020		$ 67,764
Balance (in shares) at Dec. 31, 2020		53,631,514
Net loss	(30,681)
Balance at Jun. 30, 2021	356,678				$ 4	436,847	(1,415)	(78,758)
Balance (in shares) at Jun. 30, 2021					44,603,731
Balance at Mar. 31, 2021	(60,616)				$ 1	656	(920)	(60,353)
Balance (in shares) at Mar. 31, 2021					1,722,099
Balance at Mar. 31, 2021		$ 231,172
Balance (in shares) at Mar. 31, 2021		109,686,035
Restricted common stock vesting, Shares					36,580
Exercise of common stock options	128					128
Exercise of common stock options, Shares					76,950
Conversion of convertible preferred stock into common stock	231,172	$ (231,172)			$ 2	231,170
Conversion of convertible preferred stock into common stock, Shares		109,686,035			31,068,102
Issuance of common stock in connection with initial public offering, net of issuance costs of $18,500	203,875				$ 1	203,874
Issuance of common stock in connection with initial public offering, net of issuance costs of $18,500, shares					11,700,000
Provision for pension benefit obligation	(495)						(495)
Stock-based compensation expense	1,019					1,019
Net loss	(18,405)							(18,405)
Balance at Jun. 30, 2021	356,678				$ 4	436,847	(1,415)	(78,758)
Balance (in shares) at Jun. 30, 2021					44,603,731
Balance at Dec. 31, 2021	347,515				$ 5	471,566	(2,021)	(122,035)
Balance (in shares) at Dec. 31, 2021					46,535,966
Restricted common stock vesting, Shares					34,505
Exercise of common stock options	153					153
Exercise of common stock options, Shares					60,240
Provision for pension benefit obligation	34						34
Stock-based compensation expense	2,251					2,251
Unrealized loss on available-for-sale securities	(146)						(146)
Net loss	(23,932)							(23,932)
Balance at Mar. 31, 2022	325,875				$ 5	473,970	(2,133)	(145,967)
Balance (in shares) at Mar. 31, 2022					46,630,711
Balance at Dec. 31, 2021	$ 347,515				$ 5	471,566	(2,021)	(122,035)
Balance (in shares) at Dec. 31, 2021					46,535,966
Exercise of common stock options, Shares	79,679
Net loss	$ (50,401)
Balance at Jun. 30, 2022	302,050				$ 5	476,939	(2,458)	(172,436)
Balance (in shares) at Jun. 30, 2022					46,684,658
Balance at Mar. 31, 2022	325,875				$ 5	473,970	(2,133)	(145,967)
Balance (in shares) at Mar. 31, 2022					46,630,711
Restricted common stock vesting, Shares					34,508
Exercise of common stock options	96					96
Exercise of common stock options, Shares					19,439
Provision for pension benefit obligation	33						33
Stock-based compensation expense	2,873					2,873
Unrealized loss on available-for-sale securities	(358)						(358)
Net loss	(26,469)							(26,469)
Balance at Jun. 30, 2022	$ 302,050				$ 5	$ 476,939	$ (2,458)	$ (172,436)
Balance (in shares) at Jun. 30, 2022					46,684,658

Condensed Combined and Consol_2

Condensed Combined and Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Stock issuance costs	$ 0
Series B Convertible Preferred Stock
Stock issuance costs of convertible securities	68
Series C Convertible Preferred Stock
Stock issuance costs of convertible securities	163
Common Stock
Stock issuance costs	$ 18,500

Condensed Combined and Consol_3

Condensed Combined and Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (50,401)	$ (30,681)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	5,124	1,271
Depreciation	1,642	741
Noncash lease expense	1,659
Net accretion of discounts/premiums on marketable securities	(331)
Changes in fair value of preferred stock tranche obligations	0	960
Gain on disposal of property and equipment	(125)
Changes in operating assets and liabilities
Prepaid expenses and other current assets	(688)	663
Accounts payable	(2,547)	(1,195)
Accrued expenses and other current liabilities	(2,196)	844
Defined benefit plan liability	28
Operating lease liability	(70)
Net cash used in operating activities	(47,905)	(27,397)
Cash flows from investing activities:
Purchases of property and equipment	(4,240)	(4,918)
Proceeds from sale of property and equipment	125
Purchases of marketable securities	(230,654)
Proceeds from maturities of marketable securities	40,000
Net cash used in investing activities	(194,769)	(4,918)
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock	0	143,000
Payment of convertible preferred stock issuance costs	0	(231)
Proceeds from initial public offering, net of underwriting discount	0	206,739
Payment of initial public offering issuance costs	0	(1,395)
Proceeds from exercise of employee stock options	249	128
Net cash provided by financing activities	249	348,241
Net (decrease) increase in cash, cash equivalents and restricted cash	(242,425)	315,926
Cash, cash equivalents and restricted cash—beginning of period	351,409	42,863
Cash, cash equivalents and restricted cash-end of period	108,984	358,789
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	103,664	357,060
Restricted cash	5,320	1,729
Total cash, cash equivalents and restricted cash	108,984	358,789
Supplemental disclosure of noncash items
Conversion of convertible preferred stock into common stock	0	231,172
Settlement of preferred stock tranche obligation	0	20,640
Common stock issuance costs in accounts payable	0	1,469
Purchases of property and equipment in accounts payable	$ 939	$ 123

Condensed Combined and Consol_4

Condensed Combined and Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Statement of Cash Flows [Abstract]
Proceeds from initial public offering, net of underwriting discount	$ 15.6	$ 15.6

Description of Business, Contri

Description of Business, Contribution and Exchange, and Liquidity	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Description of Business, Contribution and Exchange, and Liquidity	1. Description of business, contribution and exchange, and liquidity Business Monte Rosa Therapeutics, Inc. is a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically-relevant proteins. As used in these condensed consolidated financial statements, unless the context otherwise requires, references to the Company or Monte Rosa refer to Monte Rosa Therapeutics, Inc. and its wholly owned subsidiaries Monte Rosa Therapeutics AG and Monte Rosa Therapeutics Securities Corp. Monte Rosa Therapeutics AG, a Swiss operating company, was incorporated under the laws of Switzerland in April 2018. Monte Rosa Therapeutics, Inc. was incorporated in Delaware in November 2019. The Company is headquartered in Boston, Massachusetts with research operations in both Boston and Basel, Switzerland. Reverse Stock Split The Company's board of directors approved a one-for-3.5305 reverse stock split of its issued and outstanding common stock and stock options and a proportional adjustment to the existing conversion ratios for the Company's preferred stock effective as of June 17, 2021. Accordingly, all share and per share amounts for all periods presented in the financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split. Initial Public Offering In June 2021 the Company completed its initial public offering, or IPO, and issued an aggregate of 11,700,000 shares of common stock at a price to the public of $ 19.00 per share. The Company received aggregate net proceeds from the IPO of $ 203.6 million, after deducting underwriting discounts and commissions of $ 15.6 million and offering costs of $ 3.1 million. In connection with the IPO, the Company granted the underwriters a 30-day option to purchase an additional 1,755,000 shares. In July 2021, the underwriters exercised the option in full and the Company issued 1,755,000 shares of common stock for aggregate net proceeds of $ 31.0 million after deducting underwriter discounts and commissions of $ 2.3 million. Immediately prior to consummation of the IPO, all outstanding shares of the Company's Series A, Series A-2, Series B and Series C convertible preferred stock were converted into 31,068,102 shares of common stock. The Company's common stock began trading on the Nasdaq Global Select Market on June 24, 2021 under the symbol “GLUE”. Liquidity considerations Since inception, the Company has devoted substantially all its efforts to business planning, research and development, recruiting management and technical staff, and raising capital and has financed its operations primarily through the issuance of convertible preferred shares and public offerings of the Company's common stock. The Company’s continued discovery and development of its product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. As of June 30, 2022, the Company had an accumulated deficit of $ 172.4 million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $ 50.4 million and $ 30.7 million for the six months ended June 30, 2022 and 2021, respectively. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to develop its product candidates. The Company currently expects that its cash, cash equivalents, and marketable securities of $ 294.1 million as of June 30, 2022 will be sufficient to fund operating expenses and capital requirements for at least 12 months from the date the condensed consolidated financial statements are issued. However, additional funding will be necessary to fund future discovery research, pre-clinical and clinical activities. The Company will seek additional funding through public financings, debt financings, collaboration agreements, strategic alliances and licensing arrangements. Although it has been successful in raising capital in the past, there is no assurance that the Company will be successful in obtaining such additional financing on terms acceptable to it, if at all, and the Company may not be able to enter into collaborations or other arrangements. If the Company is unable to obtain funding, it could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect the Company’s business prospects, even the ability to continue operations.

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of significant accounting policies	2. Summary of significant accounting policies Basis of presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and are stated in U.S. dollars. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Updates, or ASUs, of the Financial Accounting Standards Board, or FASB. All intercompany balances and transactions have been eliminated in consolidation. Unaudited Financial Information The Company’s condensed consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and pursuant to the rules and regulations of the SEC. In the Company’s opinion, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the financial position and results of operations for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. Recently issued accounting pronouncements The Company has elected to use the extended transition period for complying with new or revised accounting standards as available under the Jumpstart Our Business Startups Act (JOBS Act). In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments . ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging , and Topic 825, Financial Instruments , or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The Company is currently assessing the potential impact of adopting ASU 2016-13 on its financial statements and financial statement disclosures. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (i) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (ii) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective for the Company beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently assessing the impact adoption of ASU 2020-06 will have on its financial statements and disclosures. Recently adopted accounting pronouncements On January 1, 2022, the Company adopted Accounting Standard Update (“ASU”) No. 2016-02, Leases (Topic 842), and its associated amendments using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. There was no cumulative-effect adjustment recorded to retained earnings upon adoption. Under the standard, a lessee is required to recognize a lease liability and right-of-use (ROU) asset for all leases. The new guidance also modified the classification criteria and requires additional disclosures to enable users of financial statements to understand the amount, timing, and uncertainty of cash flows arising from leases. Consistent with current guidance, a lessee’s recognition, measurement, and presentation of expenses and cash flows arising from a lease continues to depend primarily on its classification. The Company elected the package of practical expedients permitted under the transition guidance, which allowed the Company to carryforward its historical lease classification, its assessment on whether a contract was or contains a lease, and its initial direct costs for any leases that existed prior to January 1, 2022. In addition, the Company elected the following transitional practical expedients: (1) the short-term lease exception and (2) to not separate its non-lease components for its real estate, vehicle and equipment leases. Upon the adoption of this standard, the Company recorded operating lease right-of-use assets of $ 7.3 million and corresponding operating lease liabilities of $ 7.4 million as of January 1, 2022. The difference between the value of the right-of-use assets and lease liabilities is due to the reclassification of existing deferred rent as of January 1, 2022. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes, or ASU 2019-12. ASU 2019-12 eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. This guidance is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company adopted ASU 2019-12 on January 1, 2022. The adoption of the standard was immaterial to the accompanying condensed consolidated financial statements.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair value measurements The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): As of June 30, 2022 Level 1 Level 2 Level 3 Total Current assets Money market funds $ 89,717 $ — $ — $ 89,717 Pension plan assets(1) — 3,748 — 3,748 Corporate debt securities — 102,951 — 102,951 U.S Treasury securities — 87,530 — 87,530 Total assets measured at fair value $ 89,717 $ 194,229 $ — $ 283,946 (1) The fair value of pension plan assets has been determined as the surrender value of the portfolio of active insured members held within the Swiss Life Collective BVG Foundation collective investment fund. Money market funds are highly liquid investments and are actively traded. The pricing information on the Company’s money market funds are based on quoted prices in active markets for identical securities. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. Marketable securities consist of corporate debt securities and U.S. Treasury securities which are classified as available-for-sale pursuant to ASC 320, Investments—Debt and Equity Securities . Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets. The fair values of these investments are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities based on historical data and other observable inputs. All marketable securities have a maturity date within the next 12 months. There were no transfers among Level 1, Level 2 or Level 3 categories in the six months ended June 30, 2022 and 2021 .

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	4. Marketable Securities Marketable securities as of June 30, 2022 consisted of the following : Amortized Unrealized Unrealized Fair Cost Gains Losses Value Description Corporate debt securities $ 103,261 $ — $ ( 310 ) $ 102,951 U.S Treasury securities 87,723 — ( 193 ) 87,530 Total $ 190,984 $ — $ ( 503 ) $ 190,481 As of June 30, 2022 , the Company held 30 marketable securities, 22 of which are in an unrealized loss position. The aggregate fair value of securities in a loss position is $ 127.7 million. There were no individual securities that were in a significant unrealized loss position as of June 30, 2022. The Company evaluates securities for other-than-temporary impairments based on quantitative and qualitative factors, and considers the decline in market value as of June 30, 2022 , to be primarily attributable to the then current economic and market conditions. The Company neither intends to sell these investments nor concludes that it is more-likely-than-not that the Company will have to sell them before recovery of their carrying values. The Company also believes that it will be able to collect both principal and interest amounts due to it at maturity.

Property and Equipment, net

Property and Equipment, net	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, net	5. Property and Equipment, net Property and equipment, net, consist of the following (in thousands): June 30, December 31, Laboratory equipment $ 16,213 $ 12,315 Computer hardware and software $ 484 443 Furniture and fixtures 299 299 Leasehold improvements 1,119 1,119 Construction in process 1,258 852 Total property and equipment, at cost $ 19,373 $ 15,028 Less: accumulated depreciation ( 4,168 ) ( 2,703 ) Property and equipment, net $ 15,205 $ 12,325 Depreciation expense for the three months ended June 30, 2022 and 2021 was $ 0.8 million and $ 0.4 million, respectively. Depreciation expense for the six months ended June 30, 2022 and 2021 was $ 1.6 million and $ 0.7 million, respectively.

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	6. Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in the condensed consolidated balance sheets. The Company has no finance leases as of June 30, 2022. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, management estimated the incremental borrowing rate based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. 645 Summer Street In September 2020, the Company entered into an operating lease agreement to lease 16,748 square feet of office and laboratory space at 645 Summer Street, Boston, Massachusetts. The original term of the 645 Summer Lease expires in March 2026 . On May 5, 2022, the Company entered into an Agreement for Termination of Lease (the “Lease Termination Agreement”) with OPG MP Parcel Owner (DE) LLC (the “Landlord”) which, subject to the Landlord executing a lease with a new tenant, provides the Company with the option to terminate the existing lease agreement (the “645 Summer Lease”) for office space located at 645 Summer Street, Boston, MA. As of June 30, 2022, the landlord had not executed a new lease with a new tenant. See Note 13 for more information. Klybeck Lease In March 2021, the Company entered into an operating lease agreement for office and lab space that occupies approximately 21,422 square feet located at Hochbergerstrasse 60C, 4057 Basel, Basel-City, Switzerland. The current term of the lease expires in March 2026. Harrison Street Lease In December, 2021, the Company entered into a non-cancelable lease agreement for 63,327 square feet of office and laboratory space to support its expanding operations. The term of the lease commenced on April 1, 2022 and the Company’s obligation to pay rent will begin upon the earlier of (a) December 1, 2022 or (b) the date which is two (2) months following the date which Company substantially completes its tenant improvements. The initial term of the lease is 128 months following the commencement date at which point the Company has the option to extend the lease an additional 5 years . As of the lease commencement date, the Company has determined that it is not reasonably certain to exercise the option to extend the lease and has not included the extension period in the lease term. The annual base rent under the Lease is $ 95.00 per square foot for the first year, which is subject to scheduled annual increases of 3 %, plus certain costs, operating expenses and property management fees. The components of lease expense for the six months ended June 30, 2022 are as follows (in thousands): Six months ended June 30, 2022 Operating lease expense $ 2,703 Variable lease expense 617 Total lease expense $ 3,320 The variable lease expenses generally include common area maintenance and property taxes. All lease related expenses have been recorded as research and development expense in the condensed consolidated statements of operations and comprehensive loss. There were no short-term lease costs in the six months ended June 30, 2022. The weighted average remaining lease term and discount rate related to the Company's leases are as follows: June 30, 2022 Weighted average remaining lease term (years) 9.8 Weighted average discount rate 9.7 % Supplemental cash flow information relating to the Company's leases for the six months ended June 30, 2022 are as follows (in thousands): Six months ended June 30, 2022 Right-of-use assets obtained in exchange for operating lease obligations $ 48,488 Cash paid for amounts included in the measurement of lease liabilities $ 712 The amortization of the ROU assets for the six months ended June 30, 2022 was $ 1.4 million. Future minimum lease payments under non-cancelable leases as of June 30, 2022 for each of the years ending December 31 are as follows (in thousands): Undiscounted lease payments Remaining 2022 $ 1,546 2023 8,162 2024 8,398 2025 8,642 2026 7,145 Thereafter 44,360 Total undiscounted minimum lease payments 78,253 Less: Imputed interest ( 29,496 ) Total operating lease liability $ 48,757 Prior to January 1, 2022, the Company accounted for its leases in accordance with ASC Topic 840, Leases . As of December 31, 2021, the Company was committed under operating leases for its corporate offices. The future minimum lease payments under non-cancelable operating leases as of December 31, 2021 were as follows: 2022 $ 3,160 2023 8,353 2024 8,583 2025 8,820 2026 7,298 Thereafter 44,360 Total future minimum lease payments $ 80,574

Common stock

Common stock	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Common stock	7. Common stock The Company’s board of directors approved a one -for-3.5305 reverse stock split of its issued and outstanding common stock and stock options and a proportional adjustment to the existing conversion ratios for the Company’s preferred stock effective as of June 17, 2021 . Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split. The Company had 500,000,000 shares of common stock authorized, of which 46,873,974 shares were issued and 46,684,658 shares were outstanding at June 30, 2022. The holders of common stock are entitled to dividends when and if declared by the board of directors. The board of directors has no t declared any dividends and the Company has no t paid any dividends. The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. The Company has issued restricted stock to founders, employees and consultants, and expense for this restricted stock is recognized on a straight-line basis (see Note 8). The restricted stock generally vests monthly over 4 years . As of June 30, 2022 and December 31, 2021, the Company has reserved the following shares of common stock for the vesting of restricted stock and exercise of stock options: June 30, December 31, Options to purchase common stock 7,192,968 5,563,513 Unvested restricted common stock 189,316 258,329 7,382,284 5,821,842

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	8. Stock-based compensation 2020 Stock incentive plan The Company’s 2020 Stock Option and Grant Plan, or the 2020 Plan, provided for the Company to grant stock options, restricted stock and other stock awards, to employees, non-employee directors, and consultants. Upon the effectiveness of the 2021 Plan (as defined below), no further issuances will be made under the 2020 Plan. 2021 Stock incentive plan The Company’s 2021 Stock Option and Incentive Plan, or the 2021 Plan, was approved by the Company’s board of directors on May 28, 2021, and the Company’s stockholders on June 17, 2021, and became effective on the date immediately prior to the date on which the registration statement for the Company’s IPO was declared effective. The 2021 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2021 Plan is 4,903,145 . As of December 31, 2021, 3,658,193 shares of common stock were available for issuance under 2021 Plan. Effective January 1, 2022, the number of shares available under the 2021 Plan automatically increased by 2,326,798 shares pursuant to the evergreen provision of the 2021 Plan. As of June 30, 2022, 4,198,022 shares were available for issuance under the 2021 Plan. Under the evergreen provision of the 2021 plan, each January 1 commencing in 2022 and thereafter automatically increases shares available for issuance by 5 % of the outstanding number of shares of the Company’s common stock on the immediately preceding December 31 or such lesser number of shares as may be determined by the Company’s compensation, nomination and corporate governance committee. 2021 Employee stock purchase plan The Company’s 2021 Employee Stock Purchase Plan, or the 2021 ESPP, was approved by the Company’s board of directors on May 28, 2021, and the Company’s stockholders on June 17, 2021, and became effective on the date immediately prior to the date on which the registration statement for the Company’s IPO was declared effective. A total of 439,849 shares of the Company’s common stock were initially reserved for issuance under the 2021 ESPP, which will be automatically increased on January 1, 2022 and will continue to increase each January 1 thereafter through January 1, 2031, by the least of (i) 439,849 shares of the Company’s common stock, (ii) 1 % of the outstanding number of shares of the Company’s common stock on the immediately preceding December 31, 2020 or (iii) such lesser number of shares of the Company’s common stock as determined by the plan administrator of the 2021 ESPP. As of December 31, 2021, 439,849 shares of common stock remained available for issuance under the 2021 ESPP. Effective January 1, 2022, the number of shares available under the 2021 ESPP automatically increased by 439,849 shares pursuant to the evergreen provision of the 2021 ESPP. As of June 30, 2022, 879,698 shares were available for issuance under the 2021 ESPP. Stock option activity The following summarizes stock option activity: Number of Weighted Weighted Aggregate Outstanding—December 31, 2021 5,563,513 $ 7.92 9.2 $ 70,045 Granted 1,845,375 13.02 — — Exercised ( 79,679 ) 3.12 — — Forfeited ( 136,241 ) 11.00 — — Outstanding—June 30, 2022 7,192,968 $ 9.22 9.0 $ 21,414 Exercisable—June 30, 2022 1,724,556 $ 6.93 8.6 $ 7,589 The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of the options and the estimated fair value of the Company’s common stock. Restricted stock award activity The following summarizes restricted stock activity: Number Weighted Unvested as of December 31, 2021 258,329 $ 0.90 Vested ( 69,013 ) $ 0.78 Unvested as of June 30, 2022 189,316 $ 0.94 The aggregate fair value of restricted stock that vested during the six months ended June 30, 2022 was $ 0.9 million. The weighted average fair value of restricted stock that vested during the six months ended June 30, 2021 was immaterial. The weighted average grant date fair value of restricted stock that vested during the six months ended June 30, 2022 was $ 0.78 . Stock-based compensation expense Stock-based compensation expense is classified as follows (in thousands): Six months ended 2022 2021 Research and development $ 2,593 $ 501 General and administrative 2,531 770 Total stock-based compensation expense $ 5,124 $ 1,271 As of June 30, 2022, total unrecognized stock–based compensation cost related to unvested stock options and restricted stock awards was $ 35.5 million and $ 0.2 million, respectively. The Company expects to recognize this remaining cost over a weighted average period of 2.9 and 1.4 years, respectively.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income taxes	. Income taxes The Company did no t record a provision or benefit for income taxes during the six months ended June 30, 2022 and 2021. The Company continues to maintain a full valuation allowance against all of its deferred tax assets. The Company has evaluated the positive and negative evidence involving its ability to realize our deferred tax assets. The Company has considered its history of cumulative net losses incurred since inception and its lack of any commercial products. The Company has concluded that it is more likely than not that it will not realize the benefits of its deferred tax assets. The Company reevaluates the positive and negative evidence at each reporting period.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Common Share	10. Net loss per common share Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands except share and per share amounts): Three months ended Six months ended 2022 2021 2022 2021 Net loss $ ( 26,469 ) $ ( 18,405 ) $ ( 50,401 ) $ ( 30,681 ) Net loss per share attributable to common stockholders—basic and diluted $ ( 0.57 ) $ ( 3.63 ) $ ( 1.08 ) $ ( 9.03 ) Weighted-average number of common shares used in computing net loss 46,668,369 5,070,554 46,632,279 3,399,174 The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share, as their effect is anti-dilutive: June 30, June 30, 2022 2021 Stock options to purchase common stock 7,192,968 5,562,928 Restricted common stock 189,316 422,133

Related Parties

Related Parties	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Parties	11. Related parties Versant Venture Management, LLC or Versant Venture has been a related party since inception of the Company as an investor and member of the board of directors. The Company had a service agreement with a Versant Venture discovery engine, Ridgeline Discovery, or Ridgeline. Ridgeline provided management and administrative support to facilitate start-up of the Company and provided research and development services. Expenses attributable to Ridgeline were recognized primarily in research and development expenses in the Company’s condensed consolidated statements of operations and comprehensive loss. The Company paid $ 2.6 million and $ 7.3 million to Ridgeline during the three and six month periods ended June 30 2021, respectively. As of June 30, 2021 the Company had $ 0.5 million in accounts payable in the condensed consolidated balance sheets associated with Ridgeline. The consulting agreement with Ridgeline expired December 31, 2021. Transactions with Versant Venture and Ridgeline for the three and six month periods ended June 30, 2022 were immaterial.

Employee Retirement Plan

Employee Retirement Plan	6 Months Ended
	Jun. 30, 2022
Retirement Benefits [Abstract]
Employee Retirement Plan	12. Employee retirement plans The Company, in compliance with Swiss Law, is contracted with the Swiss Life Collective BVG Foundation for the provision of pension benefits in a defined benefit plan. All benefits are reinsured in their entirety with Swiss Life Ltd within the framework of the contract. The technical administration and management of the savings account are guaranteed by Swiss Life on behalf of the collective foundation. Insurance benefits due are paid directly to the entitled persons by Swiss Life in the name of and for the account of the collective foundation. The pension plan is financed by contributions of both employees and employer. The contract between the Company and the collective foundation can be terminated by either side. In the event of a termination, the Company would have an obligation to find alternative pension arrangements for its employees. Because there is no guarantee that the employee pension arrangements would be continued under the same conditions, there is a risk, albeit remote, that a pension obligation may fall on the Company. The pension assets are pooled for all affiliated companies; the investment of assets is done by the governing bodies of the collective foundation or by mandated parties. The risks of disability, death and longevity are reinsured in their entirety with Swiss Life Ltd. The Company recorded $ 0.2 million and $ 0.1 million defined benefit related expense during the three months ended June 30, 2022 and 2021, respectively. The Company recorded $ 0.4 million and $ 0.2 million defined benefit related expense during the six months ended June 30, 2022 and 2021, respectively. In February 2021, the Company adopted a defined contribution plan intended to qualify under Section 401(k) of the Internal Revenue Code covering all eligible U.S. based employees of the Company. All employees are eligible to become participants of the plan immediately upon hire. Each active employee may elect, voluntarily, to contribute a percentage of their compensation to the plan each year, subject to certain limitations. The Company reserves the right, but is not obligated, to make additional contributions to this plan. The Company makes safe-harbor match contributions of 100 % of the first 4 % of each participant’s eligible compensation. The Company recorded $ 0.1 million and $ 0.1 million matching 401(k) contribution related expense during the three months ended June 30, 2022 and 2021, respectively. The Company recorded $ 0.3 million and $ 0.1 million matching 401(k) contribution related expense during the six months ended June 30, 2022 and 2021 , respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent events The Company has evaluated subsequent events through the date these financial statements were issued and has determined that there have been no events that have occurred that would require adjustments to the Company’s disclosures in the condensed consolidated financial statements, except as referenced below. On May 5, 2022, the Company and entered into an agreement for the termination of lease the Company's office located at 645 Summer Street Boston, Massachusetts subject to the termination condition of the landlord and a new tenant executing a new lease for the premises. On August 8, 2022, the termination condition was met. The Company may terminate the lease as of any date between February 1, 2023 and June 1, 2023 upon providing 90 days prior notice of such date. As of June 30, 2022, the operating lease ROU asset and operating lease liability related to the 645 Summer Street Lease was $ 5.1 million and $ 5.2 million, respectively. If the termination condition had been met as of June 30, 2022, the ROU asset and operating lease liability would have been reduced by $ 3.7 million to $ 1.4 million and $ 1.5 million, respectively.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and are stated in U.S. dollars. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Updates, or ASUs, of the Financial Accounting Standards Board, or FASB. All intercompany balances and transactions have been eliminated in consolidation.
Initial Public Offering	Initial Public Offering In June 2021 the Company completed its initial public offering, or IPO, and issued an aggregate of 11,700,000 shares of common stock at a price to the public of $ 19.00 per share. The Company received aggregate net proceeds from the IPO of $ 203.6 million, after deducting underwriting discounts and commissions of $ 15.6 million and offering costs of $ 3.1 million. In connection with the IPO, the Company granted the underwriters a 30-day option to purchase an additional 1,755,000 shares. In July 2021, the underwriters exercised the option in full and the Company issued 1,755,000 shares of common stock for aggregate net proceeds of $ 31.0 million after deducting underwriter discounts and commissions of $ 2.3 million. Immediately prior to consummation of the IPO, all outstanding shares of the Company's Series A, Series A-2, Series B and Series C convertible preferred stock were converted into 31,068,102 shares of common stock. The Company's common stock began trading on the Nasdaq Global Select Market on June 24, 2021 under the symbol “GLUE”.
Liquidity Consideration	Liquidity considerations Since inception, the Company has devoted substantially all its efforts to business planning, research and development, recruiting management and technical staff, and raising capital and has financed its operations primarily through the issuance of convertible preferred shares and public offerings of the Company's common stock. The Company’s continued discovery and development of its product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. As of June 30, 2022, the Company had an accumulated deficit of $ 172.4 million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $ 50.4 million and $ 30.7 million for the six months ended June 30, 2022 and 2021, respectively. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to develop its product candidates. The Company currently expects that its cash, cash equivalents, and marketable securities of $ 294.1 million as of June 30, 2022 will be sufficient to fund operating expenses and capital requirements for at least 12 months from the date the condensed consolidated financial statements are issued. However, additional funding will be necessary to fund future discovery research, pre-clinical and clinical activities. The Company will seek additional funding through public financings, debt financings, collaboration agreements, strategic alliances and licensing arrangements. Although it has been successful in raising capital in the past, there is no assurance that the Company will be successful in obtaining such additional financing on terms acceptable to it, if at all, and the Company may not be able to enter into collaborations or other arrangements. If the Company is unable to obtain funding, it could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect the Company’s business prospects, even the ability to continue operations.
Unaudited Financial Information	Unaudited Financial Information The Company’s condensed consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and pursuant to the rules and regulations of the SEC. In the Company’s opinion, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the financial position and results of operations for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.
Recently Issued Accounting Pronouncements	Recently issued accounting pronouncements The Company has elected to use the extended transition period for complying with new or revised accounting standards as available under the Jumpstart Our Business Startups Act (JOBS Act). In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments . ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging , and Topic 825, Financial Instruments , or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The Company is currently assessing the potential impact of adopting ASU 2016-13 on its financial statements and financial statement disclosures. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (i) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (ii) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective for the Company beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently assessing the impact adoption of ASU 2020-06 will have on its financial statements and disclosures. Recently adopted accounting pronouncements On January 1, 2022, the Company adopted Accounting Standard Update (“ASU”) No. 2016-02, Leases (Topic 842), and its associated amendments using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. There was no cumulative-effect adjustment recorded to retained earnings upon adoption. Under the standard, a lessee is required to recognize a lease liability and right-of-use (ROU) asset for all leases. The new guidance also modified the classification criteria and requires additional disclosures to enable users of financial statements to understand the amount, timing, and uncertainty of cash flows arising from leases. Consistent with current guidance, a lessee’s recognition, measurement, and presentation of expenses and cash flows arising from a lease continues to depend primarily on its classification. The Company elected the package of practical expedients permitted under the transition guidance, which allowed the Company to carryforward its historical lease classification, its assessment on whether a contract was or contains a lease, and its initial direct costs for any leases that existed prior to January 1, 2022. In addition, the Company elected the following transitional practical expedients: (1) the short-term lease exception and (2) to not separate its non-lease components for its real estate, vehicle and equipment leases. Upon the adoption of this standard, the Company recorded operating lease right-of-use assets of $ 7.3 million and corresponding operating lease liabilities of $ 7.4 million as of January 1, 2022. The difference between the value of the right-of-use assets and lease liabilities is due to the reclassification of existing deferred rent as of January 1, 2022. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes, or ASU 2019-12. ASU 2019-12 eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. This guidance is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company adopted ASU 2019-12 on January 1, 2022. The adoption of the standard was immaterial to the accompanying condensed consolidated financial statements.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): As of June 30, 2022 Level 1 Level 2 Level 3 Total Current assets Money market funds $ 89,717 $ — $ — $ 89,717 Pension plan assets(1) — 3,748 — 3,748 Corporate debt securities — 102,951 — 102,951 U.S Treasury securities — 87,530 — 87,530 Total assets measured at fair value $ 89,717 $ 194,229 $ — $ 283,946 (1) The fair value of pension plan assets has been determined as the surrender value of the portfolio of active insured members held within the Swiss Life Collective BVG Foundation collective investment fund.

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Summary of Marketable securities	Marketable securities as of June 30, 2022 consisted of the following : Amortized Unrealized Unrealized Fair Cost Gains Losses Value Description Corporate debt securities $ 103,261 $ — $ ( 310 ) $ 102,951 U.S Treasury securities 87,723 — ( 193 ) 87,530 Total $ 190,984 $ — $ ( 503 ) $ 190,481

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net, consist of the following (in thousands): June 30, December 31, Laboratory equipment $ 16,213 $ 12,315 Computer hardware and software $ 484 443 Furniture and fixtures 299 299 Leasehold improvements 1,119 1,119 Construction in process 1,258 852 Total property and equipment, at cost $ 19,373 $ 15,028 Less: accumulated depreciation ( 4,168 ) ( 2,703 ) Property and equipment, net $ 15,205 $ 12,325

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Summary of Lease Expense	The components of lease expense for the six months ended June 30, 2022 are as follows (in thousands): Six months ended June 30, 2022 Operating lease expense $ 2,703 Variable lease expense 617 Total lease expense $ 3,320
Schedule of Lease Terms and Discount Rate	The weighted average remaining lease term and discount rate related to the Company's leases are as follows: June 30, 2022 Weighted average remaining lease term (years) 9.8 Weighted average discount rate 9.7 %
Schedule Of Supplemental Cash Flow Information Related To Leases	Supplemental cash flow information relating to the Company's leases for the six months ended June 30, 2022 are as follows (in thousands): Six months ended June 30, 2022 Right-of-use assets obtained in exchange for operating lease obligations $ 48,488 Cash paid for amounts included in the measurement of lease liabilities $ 712
Schedule of Future Minimum Payments Under Non -cancelable Operating Leases	Future minimum lease payments under non-cancelable leases as of June 30, 2022 for each of the years ending December 31 are as follows (in thousands): Undiscounted lease payments Remaining 2022 $ 1,546 2023 8,162 2024 8,398 2025 8,642 2026 7,145 Thereafter 44,360 Total undiscounted minimum lease payments 78,253 Less: Imputed interest ( 29,496 ) Total operating lease liability $ 48,757
Schedule of Future Minimum Rental Payments for Operating Leases under non-cancelable	The future minimum lease payments under non-cancelable operating leases as of December 31, 2021 were as follows: 2022 $ 3,160 2023 8,353 2024 8,583 2025 8,820 2026 7,298 Thereafter 44,360 Total future minimum lease payments $ 80,574

Common stock (Tables)

Common stock (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Common Stock Reserved for Potential Conversion of Outstanding Preferred Stock, Vesting of Restricted Stock and Exercise of Stock Options	As of June 30, 2022 and December 31, 2021, the Company has reserved the following shares of common stock for the vesting of restricted stock and exercise of stock options: June 30, December 31, Options to purchase common stock 7,192,968 5,563,513 Unvested restricted common stock 189,316 258,329 7,382,284 5,821,842

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	The following summarizes stock option activity: Number of Weighted Weighted Aggregate Outstanding—December 31, 2021 5,563,513 $ 7.92 9.2 $ 70,045 Granted 1,845,375 13.02 — — Exercised ( 79,679 ) 3.12 — — Forfeited ( 136,241 ) 11.00 — — Outstanding—June 30, 2022 7,192,968 $ 9.22 9.0 $ 21,414 Exercisable—June 30, 2022 1,724,556 $ 6.93 8.6 $ 7,589
Schedule of Restricted Stock Award Activity	The following summarizes restricted stock activity: Number Weighted Unvested as of December 31, 2021 258,329 $ 0.90 Vested ( 69,013 ) $ 0.78 Unvested as of June 30, 2022 189,316 $ 0.94
Schedule of Stock Based Compensation Expense	Stock-based compensation expense is classified as follows (in thousands): Six months ended 2022 2021 Research and development $ 2,593 $ 501 General and administrative 2,531 770 Total stock-based compensation expense $ 5,124 $ 1,271

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands except share and per share amounts): Three months ended Six months ended 2022 2021 2022 2021 Net loss $ ( 26,469 ) $ ( 18,405 ) $ ( 50,401 ) $ ( 30,681 ) Net loss per share attributable to common stockholders—basic and diluted $ ( 0.57 ) $ ( 3.63 ) $ ( 1.08 ) $ ( 9.03 ) Weighted-average number of common shares used in computing net loss 46,668,369 5,070,554 46,632,279 3,399,174
Schedule of Antidilutive Securities Excluded from Earnings Per Share Calculation	The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share, as their effect is anti-dilutive: June 30, June 30, 2022 2021 Stock options to purchase common stock 7,192,968 5,562,928 Restricted common stock 189,316 422,133

Description of Business, Cont_2

Description of Business, Contribution and Exchange, and Liquidity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended				6 Months Ended
	Jul. 23, 2021	Jun. 17, 2021	Jun. 30, 2021	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Subsidiary Or Equity Method Investee [Line Items]
Common stock shares issued				46,873,974				46,873,974		46,794,295
Common stock par or stated value per share				$ 0.0001				$ 0.0001		$ 0.0001
Proceeds from initial public offering, net of underwriting discount								$ 0	$ 206,739
Stockholders' equity, reverse stock split		one-for-3.5305						The Company’s board of directors approved a one-for-3.5305 reverse stock split of its issued and outstanding common stock and stock options and a proportional adjustment to the existing conversion ratios for the Company’s preferred stock effective as of June 17, 2021
Restricted Cash and Cash Equivalents				$ 294,100				$ 294,100
Accumulated deficit				(172,436)				(172,436)		$ (122,035)
Net loss				(26,469)	$ (23,932)	$ (18,405)	$ (12,276)	(50,401)	(30,681)
Cash and cash equivalents at carrying value			$ 357,060	$ 103,664		$ 357,060		$ 103,664	$ 357,060	$ 346,071
Common Stock
Subsidiary Or Equity Method Investee [Line Items]
Stock Issued during period, for conversion of convertible securities			31,068,102
IPO
Subsidiary Or Equity Method Investee [Line Items]
Common stock shares issued	1,755,000		11,700,000			11,700,000			11,700,000
Common stock par or stated value per share				$ 19				$ 19
Proceeds from issuance of common stock	$ 31,000
Proceeds from initial public offering, net of underwriting discount								$ 203,600
Underwriting discount and commission	$ 2,300							15,600
Offering Costs								$ 3,100

Summary of significant accoun_3

Summary of significant accounting policies (Additional Information) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jan. 01, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Operating lease right-of-use assets	$ 47,102	$ 7,300	$ 0
Operating lease liability		$ 7,400

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets Liabilities Measured on Recurring Basis (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Current assets
Total assets measured at fair value	$ 283,946
Level 1
Current assets
Total assets measured at fair value	89,717
Level 2
Current assets
Total assets measured at fair value	194,229
Level 3
Current assets
Total assets measured at fair value	0
Corporate Debt Securities
Current assets
Total assets measured at fair value	102,951
Corporate Debt Securities | Level 1
Current assets
Total assets measured at fair value
Corporate Debt Securities | Level 2
Current assets
Total assets measured at fair value	102,951
Corporate Debt Securities | Level 3
Current assets
Total assets measured at fair value
US Treasury Securities
Current assets
Total assets measured at fair value	87,530
US Treasury Securities | Level 1
Current assets
Total assets measured at fair value
US Treasury Securities | Level 2
Current assets
Total assets measured at fair value	87,530
US Treasury Securities | Level 3
Current assets
Total assets measured at fair value
Money Market Funds
Current assets
Total assets measured at fair value	89,717
Money Market Funds | Level 1
Current assets
Total assets measured at fair value	89,717
Money Market Funds | Level 2
Current assets
Total assets measured at fair value	0
Money Market Funds | Level 3
Current assets
Total assets measured at fair value	0
Pension Plan Assets
Current assets
Total assets measured at fair value	3,748	[1]
Pension Plan Assets | Level 1
Current assets
Total assets measured at fair value	0	[1]
Pension Plan Assets | Level 2
Current assets
Total assets measured at fair value	3,748	[1]
Pension Plan Assets | Level 3
Current assets
Total assets measured at fair value	$ 0	[1]
[1] The fair value of pension plan assets has been determined as the surrender value of the portfolio of active insured members held within the Swiss Life Collective BVG Foundation collective investment fund.

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Measure at fair value, transfers among Level 1, Level 2 or Level 3	$ 0	$ 0

Marketable Securities (Addition

Marketable Securities (Additional Information) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($) Security
Investments, Debt and Equity Securities [Abstract]
Debt Securities, Available-for-Sale, Unrealized Loss Position | $	$ 127.7
Number of marketable securities held | Security	30

Marketable Securities - Summary

Marketable Securities - Summary of Marketable securities (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Marketable Securities [Line Items]
Amortized Cost	$ 190,984
Unrealized Gains	0
Unrealized Losses	(503)
Fair Value	190,481
US Treasury Securities
Marketable Securities [Line Items]
Amortized Cost	87,723
Unrealized Gains	0
Unrealized Losses	(193)
Fair Value	87,530
Corporate Debt Securities
Marketable Securities [Line Items]
Amortized Cost	103,261
Unrealized Gains	0
Unrealized Losses	(310)
Fair Value	$ 102,951

Property and Equipment, net - S

Property and Equipment, net - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	$ 19,373	$ 15,028
Less: accumulated depreciation	(4,168)	(2,703)
Property and equipment, net	15,205	12,325
Laboratory Equipment
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	16,213	12,315
Computer Hardware and Software
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	484	443
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	299	299
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	1,119	1,119
Construction in process
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	$ 1,258	$ 852

Property and Equipment, net - A

Property and Equipment, net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 800	$ 400	$ 1,642	$ 741

Leases (Additional Information)

Leases (Additional Information) (Details)		6 Months Ended
	Dec. 14, 2021 USD ($) ft²	Jun. 30, 2022 USD ($)	Jan. 01, 2021 ft²	Jan. 01, 2020 ft²
Lessee, Lease, Description [Line Items]
Finance Lease		$ 0
Short-Term Lease		0
Amortization of the ROU assets		$ 1,400,000
Lease expiration date		Mar. 31, 2026
645 Summer Street [Member]
Lessee, Lease, Description [Line Items]
Land Subject to Ground Leases | ft²				16,748
Hochbergerstrasse [Member]
Lessee, Lease, Description [Line Items]
Land Subject to Ground Leases | ft²			21,422
Harrison Street [Member]
Lessee, Lease, Description [Line Items]
Land Subject to Ground Leases | ft²	63,327
Lease commencement date	Apr. 01, 2022
Initial lease term	128 months
Renewal term	5 years
Lease annual base rent per square foot	$ 95
Increase in annual base rent (Percentage)	3%

Leases - Summary of Lease Expen

Leases - Summary of Lease Expense (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Leases [Abstract]
Operating lease expense	$ 2,703
Variable lease expense	617
Total lease expense	$ 3,320

Leases - Schedule of Lease Term

Leases - Schedule of Lease Terms and Discount Rate (Details)	Jun. 30, 2022
Leases [Abstract]
Weighted average remaining lease term (years)	9 years 9 months 18 days
Weighted average discount rate	9.70%

Leases - Schedule Of Supplement

Leases - Schedule Of Supplemental Cash Flow Information Related To Leases (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Leases [Abstract]
Right-of-use assets obtained in exchange for operating lease obligations	$ 48,488
Cash paid for amounts included in the measurement of lease liabilities	$ 712

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Payments Under Non -cancelable Operating Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jan. 01, 2022
Finite-Lived Intangible Assets [Line Items]
Total operating lease liability		$ 7,400
Non-cancelable leases [Member]
Finite-Lived Intangible Assets [Line Items]
Remaining 2022	$ 1,546
2023	8,162
2024	8,398
2025	8,642
2026	7,145
Thereafter	44,360
Total undiscounted minimum lease payments	78,253
Less: Imputed interest	(29,496)
Total operating lease liability	$ 48,757

Leases - Schedule of Future M_2

Leases - Schedule of Future Minimum Rental Payments for Operating Leases under non-cancelable (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Leases [Abstract]
2022	$ 3,160
2023	8,353
2024	8,583
2025	8,820
2026	7,298
Thereafter	44,360
Total future minimum lease payments	$ 80,574

Convertible Preferred Stock - A

Convertible Preferred Stock - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Class Of Stock [Line Items]
Payments of stock issuance costs	$ 0	$ 231

Common stock (Additional Inform

Common stock (Additional Information) (Details)		6 Months Ended
	Jun. 17, 2021	Jun. 30, 2022 USD ($) shares	Dec. 31, 2021 shares
Class of Stock [Line Items]
Common stock, shares authorized		500,000,000	500,000,000
Common stock shares issued		46,873,974	46,794,295
Stock Split Conversion Ratio	1
Common stock shares outstanding		46,684,658	46,535,966
Dividends declared | $		$ 0
Dividends paid | $		$ 0
Common stock, voting rights		one
Restricted Stock
Class of Stock [Line Items]
Vesting term		4 years

Common stock - Schedule of Comm

Common stock - Schedule of Common Stock for Potential Conversion Outstanding Preferred Stock (Details) - shares	Jun. 30, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Common stock reserved for future issuance	7,382,284	5,821,842
Options to Purchase Common Stock
Class Of Stock [Line Items]
Common stock reserved for future issuance	7,192,968	5,563,513
Restricted Stock
Class Of Stock [Line Items]
Common stock reserved for future issuance	189,316	258,329

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended
	Jan. 01, 2022	Jun. 30, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance		7,382,284	5,821,842
Common stock, shares, issued		46,873,974	46,794,295
Aggregate fair value of restricted stock vested		$ 0.9
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average grant date fair value, vested		$ 0.78
Unrecognized stock based compensation cost		$ 0.2
Expected remaining cost, weighted average period		1 year 4 months 24 days
Unvested Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock based compensation cost		$ 35.5
Expected remaining cost, weighted average period		2 years 10 months 24 days
2021 Stock Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	4,903,145
Increase in share percentage		5%
Number of share increase	2,326,798
Shares Issued		4,198,022	3,658,193
2021 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance		439,849
Increase in share percentage		1%
Number of share increase		439,849
Shares Issued		879,698
Common stock, shares, issued			439,849

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of options, beginning balance | shares	5,563,513
Number of options, granted | shares	1,845,375
Number of options, exercised | shares	(79,679)
Number of options, forfeited | shares	(136,241)
Number of options, ending balance | shares	7,192,968	5,563,513
Number of options, exercisable | shares	1,724,556
Weighted average exercise price, beginning balance | $ / shares	$ 7.92
Weighted average exercise price, granted | $ / shares	13.02
Weighted average exercise price, exercised | $ / shares	3.12
Weighted average exercise price, forfeited | $ / shares	11
Weighted average exercise price, ending balance | $ / shares	9.22	$ 7.92
Weighted average exercise price, exercisable | $ / shares	$ 6.93
Weighted average remaining contractual term (years), balance	9 years	9 years 2 months 12 days
Weighted average remaining contractual term (years), exercisable	8 years 7 months 6 days
Aggregate intrinsic value, beginning balance | $	$ 70,045
Aggregate intrinsic value, ending balance | $	21,414	$ 70,045
Aggregate intrinsic value, exercisable | $	$ 7,589

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Restricted Stock Award Activity (Details) - Restricted Stock	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, Unvested, beginning balance | shares	258,329
Number of shares, Vested | shares	(69,013)
Number of shares, Unvested, ending balance | shares	189,316
Weighted average grant date fair value, beginning balance | $ / shares	$ 0.90
Weighted average grant date fair value, vested | $ / shares	0.78
Weighted average grant date fair value, ending balance | $ / shares	$ 0.94

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 5,124	$ 1,271
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	2,593	501
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,531	$ 770

Income taxes - Additional Infor

Income taxes - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Provision or benefit for income tax	$ 0	$ 0

Net Loss Per Share (Schedule of

Net Loss Per Share (Schedule of Earnings Per Share, Basic and Diluted) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Net loss	$ (26,469)	$ (23,932)	$ (18,405)	$ (12,276)	$ (50,401)	$ (30,681)
Net loss per share attributable to common stockholders-basic	$ (0.57)		$ (3.63)		$ (1.08)	$ (9.03)
Net loss per share attributable to common stockholders-diluted	$ (0.57)		$ (3.63)		$ (1.08)	$ (9.03)
Weighted-average number of common shares used in computing net loss per share-basic	46,668,369		5,070,554		46,632,279	3,399,174
Weighted-average number of common shares used in computing net loss per share-diluted	46,668,369		5,070,554		46,632,279	3,399,174

Net Loss Per Share (Schedule _2

Net Loss Per Share (Schedule of Anti-Dilutive Shares Excluded from Earnings Per Share Calculation) (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Stock Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of EPS	7,192,968	5,562,928
Restricted Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of EPS	189,316	422,133

Related Parties - Additional In

Related Parties - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Related Party Transaction [Line Items]
Research and development	$ 20,936	$ 14,637	$ 38,851	$ 23,910
General and administrative expense	$ 6,295	3,486	$ 12,682	5,717
Ridgeline
Related Party Transaction [Line Items]
Research and development		2,600		7,300
Accounts payable		$ 500		$ 500

Employee Retirement Plan - Addi

Employee Retirement Plan - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Retirement Benefits [Abstract]
Defined benefit plan expenses	$ 0.2	$ 0.1	$ 0.4	$ 0.2
Percentage of company's matching contribution with respect to each participant's contribution			4%
Company matching contributions to maximum employees eligible compensation			100%
Total company contributions to 401 (k) plan	$ 0.1	$ 0.1	$ 0.3	$ 0.1

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jan. 01, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Lease termination, description	The Company may terminate the lease as of any date between February 1, 2023 and June 1, 2023 upon providing 90 days prior notice of such date.
Operating lease right-of-use assets	$ 47,102		$ 7,300	$ 0
Operating lease liability			$ 7,400
Decrease in operating lease liability	(70)
645 Summer Street [Member]
Subsequent Event [Line Items]
Operating lease right-of-use assets	5,100
Operating lease liability	5,200
Increase Decrease in Operating Lease Right of Use Asset and Liability	3,700
Decrease in operating lease right of use asset	1,400
Decrease in operating lease liability	$ 1,500